LY-364947, also known as HTS 466284, is primarily used in research settings as a selective inhibitor of the transforming growth factor-beta (TGF-β) type I receptor, also known as ALK5. Its application is significant in the study of cellular processes and signaling pathways influenced by TGF-β, which plays a crucial role in various biological functions such as cell proliferation, differentiation, and apoptosis. Researchers utilize this compound to investigate the effects of TGF-β signaling in diseases like fibrosis, cancer, and autoimmune disorders. By inhibiting ALK5, LY-364947 helps elucidate the therapeutic potential of targeting TGF-β pathways in these conditions. Additionally, it serves as a valuable tool in drug discovery and development, aiding in the identification of novel treatments for TGF-β-related pathologies.